• 1. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 2. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 3. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 4. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 5. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615

Introduction to 1-(4-Bromophenyl)-1H-indazole-3-carboxylic acid (CAS No. 885275-47-8)

1-(4-Bromophenyl)-1H-indazole-3-carboxylic acid, identified by the Chemical Abstracts Service Number (CAS No.) 885275-47-8, is a significant compound in the realm of pharmaceutical and chemical research. This heterocyclic aromatic acid has garnered attention due to its structural properties and potential applications in medicinal chemistry. The presence of both bromine and carboxylic acid functional groups makes it a versatile intermediate for synthesizing more complex molecules, particularly in the development of novel therapeutic agents.

The indazole core is a privileged scaffold in drug discovery, known for its role in various bioactive molecules. Its fused benzene and pyrrole rings provide a rigid structure that can interact effectively with biological targets. In the case of 1-(4-Bromophenyl)-1H-indazole-3-carboxylic acid, the bromine substituent at the para position of the phenyl ring enhances its reactivity, allowing for further functionalization through cross-coupling reactions such as Suzuki or Buchwald-Hartwig couplings. This makes it a valuable building block for constructing more intricate pharmacophores.

Recent advancements in medicinal chemistry have highlighted the importance of indazole derivatives in addressing various diseases, including cancer, inflammation, and infectious disorders. The carboxylic acid moiety in 1-(4-Bromophenyl)-1H-indazole-3-carboxylic acid not only serves as a site for further derivatization but also contributes to the compound's solubility and bioavailability, crucial factors in drug development.

One of the most promising applications of this compound is in the synthesis of small-molecule inhibitors targeting specific enzymes or receptors involved in disease pathways. For instance, studies have shown that indazole derivatives can modulate kinases and other enzymes implicated in cancer progression. The bromine atom's ability to participate in metal-catalyzed reactions has enabled researchers to develop novel inhibitors with improved selectivity and potency. This has been particularly relevant in the quest for targeted therapies that minimize side effects associated with traditional chemotherapeutic agents.

The pharmaceutical industry has been increasingly interested in exploring new chemical entities derived from indazole scaffolds due to their demonstrated biological activity. 1-(4-Bromophenyl)-1H-indazole-3-carboxylic acid exemplifies this trend, as it combines structural features that are conducive to drug-like properties such as metabolic stability, oral bioavailability, and binding affinity.

In addition to its role as an intermediate, 1-(4-Bromophenyl)-1H-indazole-3-carboxylic acid has been investigated for its potential antimicrobial properties. Preliminary studies suggest that certain indazole derivatives exhibit activity against resistant bacterial strains, making them attractive candidates for developing new antibiotics. The carboxylic acid group can be further functionalized to introduce additional pharmacophoric elements that enhance antimicrobial efficacy while reducing toxicity.

The synthesis of 1-(4-Bromophenyl)-1H-indazole-3-carboxylic acid typically involves multi-step organic transformations starting from readily available precursors. The bromination step at the phenyl ring is critical and can be achieved using standard brominating agents under controlled conditions. Subsequent carboxylation at the indazole ring can be accomplished through various methods, including oxidation of a methyl or ethyl side chain followed by hydrolysis.

The compound's stability under various storage conditions is another important consideration in pharmaceutical applications. Proper handling and purification techniques are essential to maintain its integrity and ensure consistent quality for subsequent synthetic steps or biological testing. High-performance liquid chromatography (HPLC) and nuclear magnetic resonance (NMR) spectroscopy are commonly employed analytical methods to confirm the compound's purity and structural identity.

Future research directions may focus on exploring the pharmacological profile of 1-(4-Bromophenyl)-1H-indazole-3-carboxylic acid derivatives using computational modeling and high-throughput screening techniques. These approaches can accelerate the identification of lead compounds with optimized properties for clinical development. Additionally, green chemistry principles may be applied to improve synthetic methodologies, reducing environmental impact while maintaining high yields and purity standards.

In conclusion, 1-(4-Bromophenyl)-1H-indazole-3-carboxylic acid (CAS No. 885275-47-8) represents a promising candidate for further exploration in drug discovery and development. Its unique structural features, combined with its reactivity and potential biological activities, make it a valuable asset in the pharmaceutical chemist's toolkit. As research continues to uncover new therapeutic targets and innovative synthetic strategies, compounds like this will play an increasingly important role in addressing unmet medical needs.

• 926692-20-8(1H-Indazole-3-carboxylic acid, 1-[1,1'-biphenyl]-4-yl-)
• 143335-20-0(1H-INDAZOLE-3-CARBOXYLIC ACID, 1-(4-BROMOPHENYL)-6-NITRO-)
• 516445-85-5(1H-INDAZOLE-3-CARBOXYLIC ACID, 6-BROMO-1-(2,4-DICHLOROPHENYL)-)
• 665020-20-2(1H-Benz[g]indazole-3-carboxylic acid, 1-phenyl-)
• 7716-36-1(1-phenylindazole-3-carboxylic acid)
• 229163-39-7(1-(4-Bromophenyl)-5-methyl-1H-pyrazole-3-carboxylic Acid)
• 36178-95-7(1H-Indazole-3-carboxylic acid, 6-amino-1-phenyl-, methyl ester)
• 1152557-01-1(1-(3-bromophenyl)-1H-pyrazole-3-carboxylic acid)
• 665020-25-7(1H-BENZ[G]INDAZOLE-3-CARBOXYLIC ACID, 1-PHENYL-, ETHYL ESTER)
• 1363380-96-4(5-Bromo-1-methyl-1H-indazole-3-carboxylic acid)